Kanamycin
| DRUG INFORMATION |
| Drug Name |
| Kanamycin |
 |
| Synonyms |
| kanamycin,Liposomal Kanamycin, KANAMYCIN A , Kanamicina [Italian], KM (the Antibiotic), Klebcil (1:1 sulfate), Kantrex (1:1 sulfate), Kanamycinum [INN-Latin], Kanamycine [INN-French], Kanamycin & CRL8131 |
| Drug Class |
| Second-Line Drugs |
| Year of Introduction |
| 1957 |
| Molecular Target |
| Ribosomal Proteins |
| Genes Involved in Drug Resistance |
| ? |
| CAS No: |
| 25389-94-0 |
| PHARMACOLOGY |
| Route |
| im |
| Side effects |
| Frequent: renal failure (usually reversible) Occasional: vestibular and auditory damage-usually irreversible; genetic predisposition possible (check family for aminoglycoside ototoxicity) |
| Toxicity |
| Medium |
| Cost |
| High |
| Usual Adult Dosage |
| 5mg/kg/day |
| Form |
| vial |
| Brand Name |
| Kantrex |
| Manufacturer |
| Generic manufacturers (Bristol-Myers Squibb; GlaxoSmithKline, ...) |
| STRUCTURAL DETAILS |
| Molecular Formula |
| C18H36N4O11 |
| Molecular Weight in g/mol |
| 484.499 |
| Hydrogen Bond Donor Count |
| 11 |
| Hydrogen Bond Acceptor Count |
| 15 |
| Rotatable Bond Count |
| 6 |
| IUPAC Name |
| 2-(aminomethyl)-6-[4,6-diamino-3-[4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-cyclohexoxy]-oxane-3,4,5-triol |
| SMILES |
| C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N |
| InChI |
| 1/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1 |
New Search